Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pleural mesothelioma

Share :
Published: 17 Sep 2021
Views: 3006
Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland

Prof Solange Peters speaks to ecancer about the 3-year update from the CheckMate 743 study.

She explains that in the randomised phase 3 CheckMate 743 study in comparison to chemotherapy, nivolumab and ipilimumab significantly prolonged overall survival in patients with unresectable malignant pleural mesothelioma.

This follow-up study reported the updated three years efficacy and safety, as well as novel biomarker analyses. Prof Peters talks about the results of this study.

She concludes by discussing the impact these results can have on the future treatment of MPS.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.